ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives.

They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops.

With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.


Biotechnology

Clearnote Health

Dave Mullarkey

Danielle Scelfo

Gulfem D. Guler

Anna Bergamaschi

Eric Nilson

Samuel Levy

Wayne Volkmuth

Jim Vaughn

The leadership team at Bluestar Genomics has a wealth of experience in the field of genomics. The team includes an adjunct professor, a staff physician, and the founder and chief scientific officer of Impact Genomics. The team also has a distinguished research fellow who has worked extensively with Quanticel Pharmaceuticals.

Leadership Team

Board of Directors

CEO and Executive Team

Leadership Team

About

Team members

Other teams at Clearnote Health

Board of Directors

CEO and Executive Team